Vesugen (Lys-Glu-Asp) | Pen

Vesugen (Lys-Glu-Asp) is a bioregulator positioned for controlled research settings where vascular endothelial function is being studied in relation to endothelial proliferation/senescence balance, oxidative-stress signaling, and microcirculatory function endpoints.

Supports

1. Endothelial proliferation and senescence-marker balance (e.g., Ki-67/p53-linked readouts) in cell models
2. Endothelial functional-activity marker profiling in aging-associated vascular paradigms
3. Oxidative-stress and antioxidant-system endpoints relevant to vascular aging models
4. Microcirculation and perfusion-related outcome frameworks in human vascular studies
5. Epigenetic/transcriptional regulation hypotheses for endothelial homeostasis in vitro

Description

Vesugen is commonly described as the tripeptide Lys-Glu-Asp (abbreviated KED), grouped with ultrashort peptide bioregulators explored as sequence-defined tools for studying tissue regulation under controlled conditions. In vascular research contexts, KED is positioned as a vasoprotective candidate peptide, particularly in experimental designs focused on endothelial aging, endothelial integrity, and stress resilience.

Published mechanistic sources propose that KED may influence endothelial functional state via epigenetic or transcription-associated regulation of genes linked to proliferation and survival, with reported effects on markers such as Ki-67 and p53 in aging endotheliocyte culture systems. These signals are typically interpreted as model-dependent and are evaluated alongside oxidative-stress and functional-activity endpoints relevant to vascular biology.

In addition to cell-model work, human clinical literature exists evaluating “Vezugen/Vesugen” in atherosclerosis-associated vascular dysfunction contexts. These studies support its use as a research-positioned compound for investigating microcirculatory and endothelial-function hypotheses, while emphasizing that outcomes depend on study design, baseline vascular status, and endpoint selection.

Clinical Status

Evidence for Vesugen/KED includes mechanistic in vitro work in endothelial aging models and review-level synthesis describing epigenetic regulation of endothelial markers. Human clinical publications have evaluated Vezugen/Vesugen in vascular dysfunction contexts associated with atherosclerosis, reporting changes in functional outcomes within specific study designs. However, regulator-approved status is not established in the provided raw text, and Vesugen is best positioned as a research tool for vascular endpoint studies rather than a validated, approved therapy.

Evidence type:
Human RCT ☐ | Observational ✔ | Animal ☐ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

Mechanistic framing for KED emphasizes sequence-dependent modulation of gene expression and protein synthesis in vascular endothelium. Epigenetic aspects of peptidergic regulation have been proposed for endothelial proliferation during aging, including promoter-level interactions and downstream shifts in proliferative and apoptosis-associated markers (e.g., increased Ki-67 and reduced p53 signals in certain endothelial culture contexts).

In vascular aging paradigms, endothelial function is closely tied to oxidative-stress balance, inflammatory signaling, and integrity of the intimal lining. Accordingly, Vesugen-focused experimental designs often pair marker-level readouts (Ki-67/p53/VEGF-associated panels) with oxidative-stress and functional-activity endpoints, and—where applicable—microcirculation outcomes in human studies to evaluate whether molecular signals align with observed functional changes.

Benefits

• Endothelial aging endpoint compatibility:
  Supports study designs tracking endothelial proliferation/senescence marker balance in aging-associated models.
• Epigenetic/transcriptional hypothesis testing:
  Useful for experiments examining gene-expression regulation mechanisms linked to endothelial functional activity.
• Oxidative-stress panel integration:
  Aligns with vascular aging frameworks that co-monitor antioxidant-system and oxidative-stress biomarkers.
• Microcirculatory outcome pairing:
  Can be incorporated into human study designs where perfusion/microcirculation endpoints are evaluated (study dependent).
• Endothelial integrity context:
  Relevant to models assessing endothelial lining integrity and apoptosis-linked risk signals in vascular stress paradigms.
• Sequence-defined vascular probe:
  Serves as a clearly defined tripeptide tool for controlled vascular biology experiments and materials documentation.

Research Data

Stack Suggestions

In extended experimental designs, Vesugen (Lys-Glu-Asp) is sometimes paired with:

• Crystagen (Glu-Asp-Pro) → to broaden immune-linked inflammation endpoints alongside vascular readouts
• Glutathione → to expand oxidative-stress and antioxidant-defense panels in vascular aging models
• Epitalon (Ala-Glu-Asp-Gly) → to compare short-peptide transcriptional signatures across aging-resilience frameworks

Stacks discussed are for experimental design only, not safety/efficacy guidance.

Possible Side Effects

There are no known reports of negative side effects.

Scientific References

• Molecular aspects of vasoprotective peptide KED activity — Review/Mechanistic
• Epigenetic Aspects of Peptidergic Regulation of Vascular Endothelial Cell Proliferation during Aging — In vitro/Mechanistic
• Senescence-Associated Secretory Phenotype of Endothelial Cells and Vascular Aging — Review
• The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people — Human (Clinical/Observational)
• The objective of the study was to assess the effectiveness of vasoactive tripeptide Vezugen in patients with vasculogenic erectile dysfunction as manifestation of atherosclerosis — Human (Clinical/Observational)
• Endogenous Vasoactive Peptides and Vascular Aging: Therapeutic Implications — Review
• Peptide Regulation of Gene Expression: A Systematic Review — Systematic review
• Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers — Review (Mechanistic)
• Peptide medicines: past, present, future — Review
• Lysyl-glutamyl-aspartic acid (Lys-Glu-Asp) — PubChem compound record — Reference (Chemical)

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.